Hyperfine (HYPR) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Hyperfine (HYPR) over the past year, gaining 116.3% versus a loss of 55.0%. Hyperfine is the larger company by market cap ($100.5 million vs $87.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | NRXS |
|---|---|---|
| Share price | $0.9478 | $6.94 |
| Market cap | $100.51M | $87.09M |
| 1-day change | +0.82% | +2.06% |
| YTD return | -3.97% | +49.12% |
| 1-year return | -55.02% | +116.29% |
| 5-year return | -90.54% | — |
| EPS (TTM) | $-0.37 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $9.33 |
| 52-week low | $0.754 | $2.21 |
| Distance from 52-week high | -57.31% | -25.67% |
| Analyst consensus | none | none |
| Avg. price target upside | +114.18% | +58.62% |
| Average volume | 765.15K | 107.27K |
| Shares outstanding | 90.99M | 12.56M |
| Employees | 102 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed HYPR by 171.3 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
HYPR vs NRXS FAQ
Which is bigger, Hyperfine or Neuraxis?
Hyperfine (HYPR) is larger, with a market capitalization of $100.51M compared with $87.09M for Neuraxis (NRXS).
Which stock has performed better over the past year, HYPR or NRXS?
NRXS returned +116.29% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.